Head-to-head evidence
Gosogliptin vs Vildagliptin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
Gosogliptin
Developed by SatRx
NCT03088670 · Phase 3 · completed
The study used randomization and an active comparator, but it was open-label and its primary endpoint was change in HbA1c, a surrogate measure rather than a hard clinical outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Vildagliptin · Galvus
Developed by Novartis
NCT00099866 · Phase 3 · completed
The study was randomized and double-blind, with an active metformin comparator and 570 participants. Its primary endpoint was the surrogate measure of HbA1c change, and because no trial results are posted, it cannot be determined whether the primary comparison was favorable.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Gosogliptin's landscape · Vildagliptin's landscape